Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy
- PMID: 3282934
Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy
Abstract
Estrogens and progestins for contraception or hormonal replacement therapy are widely used by practitioners. These steroids have substantial effects on lipids and lipoproteins that appear to be primarily related to chemical structure of the compound, dosage, and a patient's hormonal status. Although the mechanisms by which alterations in lipid and lipoproteins affect atherogenesis are not fully understood, epidemiologic studies clearly associate alterations with risk of coronary heart disease. Attention to these alterations by progestins and estrogens, as well as further research on how these steroids may exert other cardiovascular effects, is important because atherosclerotic heart disease is a major cause of morbidity and mortality for women as they age.
PIP: The use of estrogens and progestins for contraception for hormonal replacement therapy has substantial effects on lipids and lipoproteins. Elevations of lipoproteins such as total cholesterol, low density lipoprotein (LDL)-C, and apoprotein B, and reduced levels of others such as high density lipoprotein (HDL)-C and apoprotein A-1, are associated with increased risk of coronary heart disease, although the exact mechanism by which such changes contribute to atheroma formation is unknown. The effect of an estrogen or progestin on the lipid profile is dependent on the chemical structure, dose, and route of administration as well as the hormonal status of the patient. Moreover, when an estrogen and progestin are combined in a therapeutic regimen, additional interactions occur that further complicate understanding of this process. Some epidemiological studies have suggested that mechanisms other than those closely associated with the lipid/lipoprotein system may be operant in the development of coronary heart disease and that the protective effects of estrogen far outweigh any adverse effects of progestin. Other studies have found an increased risk of coronary heart disease among past oral contraceptive users. Since atherosclerotic heart disease is a major cause of morbidity and mortality for women as they age (a cumulative mortality for women 55-75 years of age of 10,500/100,000), further research on the effects of steroids on cardiovascular factors is urgently needed.
Similar articles
-
Women, lipoproteins and cardiovascular disease risk.Can J Cardiol. 1990 May;6 Suppl B:23B-29B. Can J Cardiol. 1990. PMID: 2188715 Review.
-
[Women and ischemic cardiopathy].Rev Clin Esp. 1989 Oct;185(6):308-15. Rev Clin Esp. 1989. PMID: 2695994 Review. Spanish.
-
The adverse effects of hormonal therapy.Cardiol Clin. 1986 Feb;4(1):145-52. Cardiol Clin. 1986. PMID: 3518931 Review.
-
[Cardiovascular risks of oral contraceptives: dose-response relationship].Contracept Fertil Sex (Paris). 1991 Apr;19(4):285-8. Contracept Fertil Sex (Paris). 1991. PMID: 12343220 French.
-
Atherosclerotic risk factors in cardiovascular disease.J Reprod Med. 1986 Sep;31(9 Suppl):906-12. J Reprod Med. 1986. PMID: 3772910
Cited by
-
Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.Drugs. 2000 Oct;60(4):721-869. doi: 10.2165/00003495-200060040-00003. Drugs. 2000. PMID: 11085198 Review.
-
The impact of D-Trp6 LH-RH on plasma lipid levels.J Assist Reprod Genet. 1996 Mar;13(3):223-7. doi: 10.1007/BF02065940. J Assist Reprod Genet. 1996. PMID: 8852883
-
Dose and time-course evaluation of a redox-based estradiol-chemical delivery system for the brain. I. Tissue distribution.Pharm Res. 1990 Oct;7(10):1061-7. doi: 10.1023/a:1015999318729. Pharm Res. 1990. PMID: 2281037
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous